CTOs on the Move


 
NICO gives hope to patients with primary and secondary brain tumors, cysts and hemorrhagic strokes.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

NICO raised $12.5M on 11/19/2018

Similar Companies

Segra

Our solution: Segra leverages expertise in biochemistry, botany, plant tissue culture, genetic testing, and production under strict regulatory environments to bring end-to-end solutions for product production and sale in the medical Cannabis space.

CytoDyn

CytoDyn is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of Human Immunodeficiency Virus (HIV) infection. We have one of the leading monoclonal antibodies under development for HIV infection, PRO 140, which prevents viral entry into healthy T-cells by blocking the HIV co-receptor CCR5. The drug candidate is also being tested for other immunological conditions, and has been granted FDA orphan drug status for the treatment of Graft versus Host Disease (GvHD) in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who are undergoing bone marrow stem cell transplantation.

Hapbee

Hapbee is the only wearable wellness technology that delivers the molecular signature of compounds (like melatonin, caffeine, CBD and many others) through magnetic waves - so you can experience the benefits digitally without any of the side effects. It puts you in control of your wellness.

Merrimack Pharmaceuticals

Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer. Merrimack seeks to gain a deeper understanding of underlying cancer biology through its systems biology-based approach and develop new insights, therapeutics and diagnostics to improve outcomes for cancer patients. Merrimack has multiple oncology therapeutics in clinical development and additional candidates in late stage preclinical development. Merrimack has a New Drug Application under review for its lead product candidate, MM-398, for the treatment of patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy.

Artisan Orthotic Prosthetic Technologies

Artisan Orthotic Prosthetic Technologies is a Tualatin, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.